August 8, 2024 10:58 AM EDT
R&D

TIG­IT drugs take an­oth­er hit as Mer­ck stops Phase 3 lung can­cer tri­al for fu­til­i­ty

Ayisha Sharma

News Reporter

Mer­ck is wind­ing down a late-stage test of its an­ti-TIG­IT can­di­date vi­bostolimab in small-cell lung can­cer af­ter it showed ear­ly signs of poor ef­fi­ca­cy, in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Gilead part­ners with AI start­up Gen­e­sis Ther­a­peu­tics to make small mol­e­cule drugs

Ex­clu­sive: A male con­tra­cep­tive may pre­vent 99% of preg­nan­cies. Now it’s up to a small biotech to fin­ish test­ing it

Adicet fol­lows oth­er cell ther­a­py biotechs in au­toim­mune piv­ot

FDA sends warn­ing let­ter to In­di­an drug­mak­er af­ter find­ing glass in in­jec­tions 

Roivant un­veils its next deal, hop­ing for TL1A-sized po­ten­tial from a shelved Bay­er lung dis­ease ther­a­py

GSK to shut down UK an­tibi­ot­ic fa­cil­i­ty fol­low­ing end of San­doz con­tract

A service from the Financial Times